- Home
- STEL vs VIR Comparison
STEL vs VIR Comparison
Compare STEL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEL
- VIR
- Stock Information
- Founded
- STEL 2007
- VIR 2016
- Country
- STEL United States
- VIR United States
- Employees
- STEL N/A
- VIR N/A
- Industry
- STEL Major Banks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- STEL Finance
- VIR Health Care
- Exchange
- STEL Nasdaq
- VIR Nasdaq
- Market Cap
- STEL 1.5B
- VIR 1.4B
- IPO Year
- STEL N/A
- VIR 2019
- Fundamental
- Price
- STEL $28.64
- VIR $9.57
- Analyst Decision
- STEL Hold
- VIR Buy
- Analyst Count
- STEL 3
- VIR 6
- Target Price
- STEL $29.67
- VIR $34.83
- AVG Volume (30 Days)
- STEL 147.0K
- VIR 1.2M
- Earning Date
- STEL 01-30-2025
- VIR 02-26-2025
- Dividend Yield
- STEL 1.96%
- VIR N/A
- EPS Growth
- STEL N/A
- VIR N/A
- EPS
- STEL 2.20
- VIR N/A
- Revenue
- STEL $433,918,000.00
- VIR $78,618,000.00
- Revenue This Year
- STEL N/A
- VIR N/A
- Revenue Next Year
- STEL $4.61
- VIR N/A
- P/E Ratio
- STEL $13.02
- VIR N/A
- Revenue Growth
- STEL N/A
- VIR N/A
- 52 Week Low
- STEL $21.27
- VIR $6.56
- 52 Week High
- STEL $32.36
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- STEL 47.65
- VIR 48.60
- Support Level
- STEL $28.56
- VIR $9.54
- Resistance Level
- STEL $29.59
- VIR $9.97
- Average True Range (ATR)
- STEL 0.69
- VIR 0.55
- MACD
- STEL -0.03
- VIR -0.08
- Stochastic Oscillator
- STEL 50.81
- VIR 39.89
About STEL Stellar Bancorp Inc.
Stellar Bancorp Inc is a U.S. based bank holding company. It mainly focuses on providing commercial banking solutions to local small and mid-sized businesses and professionals. The services provided by the company include business and personal deposits account, personal and business lending, mobile and online banking, merchant banking, and others. The company more than 50 full service banking centers.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.